ATE406443T1 - Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung - Google Patents

Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung

Info

Publication number
ATE406443T1
ATE406443T1 AT02720601T AT02720601T ATE406443T1 AT E406443 T1 ATE406443 T1 AT E406443T1 AT 02720601 T AT02720601 T AT 02720601T AT 02720601 T AT02720601 T AT 02720601T AT E406443 T1 ATE406443 T1 AT E406443T1
Authority
AT
Austria
Prior art keywords
gene
coupled receptor
revealed
protein
histamine
Prior art date
Application number
AT02720601T
Other languages
English (en)
Inventor
Tomoyasu Sugiyama
Noriyuki Morikawa
Ai Wakamatsu
Tamaki Oda
Ryotaro Irie
Takao Isogai
Yasuhiko Masuho
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE406443T1 publication Critical patent/ATE406443T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
AT02720601T 2001-04-25 2002-04-25 Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung ATE406443T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001127836 2001-04-25

Publications (1)

Publication Number Publication Date
ATE406443T1 true ATE406443T1 (de) 2008-09-15

Family

ID=18976638

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02720601T ATE406443T1 (de) 2001-04-25 2002-04-25 Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung

Country Status (7)

Country Link
US (2) US20040147720A1 (de)
EP (1) EP1382678B1 (de)
JP (1) JPWO2002088355A1 (de)
AT (1) ATE406443T1 (de)
DE (1) DE60228559D1 (de)
ES (1) ES2311601T3 (de)
WO (1) WO2002088355A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198914B2 (en) 2000-11-17 2007-04-03 Banyu Pharmaceutical Co., Ltd. Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37
JP2005520498A (ja) * 2001-12-17 2005-07-14 ノバルティス アクチエンゲゼルシャフト 新規ｇタンパク質共役受容体およびそのｄｎａ配列
CN109072242A (zh) * 2016-02-23 2018-12-21 科罗拉多州立大学董事会法人团体 用于治疗神经损伤的基于肽的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119493A1 (en) * 2000-07-21 2002-08-29 Glucksmann Maria Alexandra 65494, a novel human G-protein-coupled receptor family member and uses thereof
CA2331154A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
KR20010080882A (ko) * 1998-10-13 2001-08-25 리처드 피. 버군 쥬니어 구성적으로 활성화된 비내생성 인간 ｇ 단백질 결합형수용체
DK1584683T3 (da) * 1998-11-20 2007-10-29 Arena Pharm Inc Human G-protein-koblet orphan receptor RUP3
CA2401290A1 (en) * 2000-04-12 2001-10-18 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
CA2413435A1 (en) * 2000-06-20 2001-12-27 Euroscreen S.A. A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists
AU2001280785A1 (en) * 2000-07-27 2002-02-13 Incyte Genomics, Inc. G-protein coupled receptors
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Also Published As

Publication number Publication date
WO2002088355A1 (fr) 2002-11-07
JPWO2002088355A1 (ja) 2004-08-19
EP1382678A1 (de) 2004-01-21
EP1382678B1 (de) 2008-08-27
US20040147720A1 (en) 2004-07-29
ES2311601T3 (es) 2009-02-16
EP1382678A4 (de) 2004-06-16
US20080171353A1 (en) 2008-07-17
DE60228559D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
Wise et al. Focus on prostacyclin and its novel mimetics
Papoff et al. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro
Nissenson et al. Synthetic peptides comprising the amino-terminal sequence of a parathyroid hormone-like protein from human malignancies. Binding to parathyroid hormone receptors and activation of adenylate cyclase in bone cells and kidney.
DE60132699T2 (de) Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
JP4409763B2 (ja) Ａｃｐｌｄｎａおよびポリペプチド
EP0538300B1 (de) O-glycosyliertes ifn-alpha
ZA943464B (en) Vascular endothelial growth factor 2
WO2001057081A3 (en) Narc-1, subtilase-like homologs
ATE253111T1 (de) Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
DE60034450D1 (de) 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase
KR20180030542A (ko) 장기-작용성 응고 인자 및 그의 제조 방법
EP1398029A8 (de) 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
WO2005001061A3 (en) Polynucleotides encoding novel adiponectin receptor variants
ATE95424T1 (de) Durch ''site-directed'' mutagenese modifzierte glukoprotein-hormone und verfahren zu deren verwendung.
Potter et al. [Pro34] neuropeptide Y selectively identifies postjunctional-mediated actions of neuropeptide Y in vivo in rats and dogs
IS6072A (is) Æðasamloðunar sameindir og mótun á starfsemi þeirra
ATE406443T1 (de) Guanosintriphosphat-bindungsprotein-gekoppelter rezeptor place 6002312 und sein gen sowie dessen produktion und verwendung
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
AU679178B2 (en) Decorin fragments and methods of inhibiting cell regulatory factors
JP3504697B2 (ja) ＰＴＨｒＰアンタゴニスト活性を有するポリペプチド及びそれを含むカルシウム代謝治療薬
WO2000050596A3 (en) 14273 receptor, a novel g-protein coupled receptor
WO2003080667A3 (en) A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
DE19860930A1 (de) Neue Sequenzvarianten des menschlichen beta2-adrenergen Rezeptorgens und ihre Verwendung
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1382678

Country of ref document: EP

REN Ceased due to non-payment of the annual fee